

Erratum

Arq Neuropsiquiatr. 2019;77(7):509-520
 Consensus of the Brazilian Headache Society on the treatment of chronic migraine
 DOI: <http://dx.doi.org/10.1590/0004-282x20190078>

The table 5:

Table 5. Oral drugs evaluated in the treatment of chronic migraine in adults: evidence of efficacy, class of recommendation, recommended doses and risk categories regarding use during pregnancy and lactation.

Drug	Evidence	Recommendation	Dose (mg/day)	Risk during pregnancy*	Risk during lactation**†	References
Neuromodulators						
Topiramate	I	A	50-200	D	L3	62, 64-66, 70
Valproate	II	B	500-2000	X	L2	71
Gabapentin	II	B	900-1800	C	L2	72
Pregabalin	III	C	125-450	C	L2	73
Zonisamide	III	C	50-200	D	L5	74
Beta-blockers						
Atenolol	III	C	50-200	C	L3	75
Tricyclics						
Amitriptyline	II	C	50-100	C	L2	76
Calcium channel blockers						
Flunarizine	III	C	10	C	L5	77
Miscellaneous						
Tizanidine	II	B	fev/24	C	L3	78

Should be:

Table 5. Oral drugs evaluated in the treatment of chronic migraine in adults: evidence of efficacy, class of recommendation, recommended doses and risk categories regarding use during pregnancy and lactation.

Drug	Evidence	Recommendation	Dose (mg/day)	Risk during pregnancy*	Risk during lactation**†	References
Neuromodulators						
Topiramate	I	A	50-200	D	L3	62, 64-66, 70
Valproate	II	B	500-2000	X	L2	71
Gabapentin	II	B	900-1800	C	L2	72
Pregabalin	III	C	125-450	C	L2	73
Zonisamide	III	C	50-200	D	L5	74
Beta-blockers						
Atenolol	III	C	50-200	C	L3	75
Tricyclics						
Amitriptyline	II	C	50-100	C	L2	76
Calcium channel blockers						
Flunarizine	III	C	10	C	L5	77
Miscellaneous						
Tizanidine	II	B	2-24	C	L3	78